ArticleBMC gastroenterology2024

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.

Laurent Peyrin-Biroulet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.